Science Updates

FDA Pipeline: Agents in DLBCL, SCLC, AML, and More

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

FDA Pipeline: Fast Track Designations in Liver and Pancreatic Cancers

Association of Immunotherapy With Survival Among Patients With Brain Metastases Whose Cancer Was Managed With Definitive Surgery of the Primary Tumor

FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer

LBA34 – Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

Combination Therapy Approved for Adults With Mesothelioma

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

New Study Offers a Global Review of the Impact of COVID-19 on Cancer Treatment and Research